...
首页> 外文期刊>Oral oncology >Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients
【24h】

Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients

机译:单页患者报告的Charlson合并症指数调查表对上消化道消化道癌症患者的验证

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: Cancer patients have a wide range of comorbidities that are important confounders for biomarker and clinical studies of prognosis and outcome. Comorbidities can be captured using the Charlson Comorbidity Index (CCI) through abstraction of medical records, but patient-reported outcome (PRO) questionnaires have also been used. The objective was to validate the PRO-CCI in a head and neck cancer (HNC) population, and to assess its level of agreement with the standard (std-CCI) method of chart review. Methods: A one-page PRO-CCI was compared with the std-CCI obtained through independent abstraction in 882 HNC patients (2007-2010). Kappa statistics and associated measures (p pos and pneg) were used to assess agreement. Discrepancy for each comorbid illness was evaluated. Proportional hazard models compared the association of std-CCI and PRO-CCI with overall survival (OS). Adjustments were made and a modified PRO-CCI was re-evaluated in a new cohort of upper aerodigestive tract cancers patient. Results: PRO-CCI was higher than the std-CCI (p 0.0001). After adjustment, having at least two comorbidities according to either the std-CCI [HR 1.97 (1.38-2.80)] or the PRO-CCI [HR 1.62 (1.18-2.24)] was prognostic. Of the most prevalent comorbidities, agreement was high for most of the CCI elements (kappa 0.76-0.93), but poorest agreement for connective tissue disease (kappa = 0.29, ppos = 43%, pneg = 84%) and COPD (kappa = 0.48, ppos = 53%, pneg = 95%). When the connective tissue disease question was modified, agreement of this item improved (kappa = 0.47, ppos = 50%). Conclusion: PRO-CCI can be an easy and effective tool in prognostic and outcomes research in HNC patients.
机译:目标:癌症患者患有多种合并症,这些合并症是生物标志物以及预后和结果临床研究的重要混杂因素。可以通过提取病历来使用Charlson合并症指数(CCI)捕获合并症,但也使用了患者报告的结局(PRO)问卷。目的是验证头颈癌(HNC)人群中的PRO-CCI,并评估其与图表审查的标准(std-CCI)方法的一致性水平。方法:比较2007年至2010年882例HNC患者的一页PRO-CCI与通过独立提取获得的std-CCI。卡帕统计数据和相关指标(p pos和pneg)用于评估一致性。评估每种合并症的差异。比例风险模型将std-CCI和PRO-CCI的关联与总生存期(OS)进行了比较。进行了调整,并对新的上消化道癌症患者队列中的改良PRO-CCI进行了重新评估。结果:PRO-CCI高于std-CCI(p <0.0001)。调整后,根据std-CCI [HR 1.97(1.38-2.80)]或PRO-CCI [HR 1.62(1.18-2.24)]具有至少两种合并症是预后的。在最普遍的合并症中,大多数CCI元素的一致性较高(kappa为0.76-0.93),而结缔组织疾病的一致性最差(kappa = 0.29,ppos = 43%,pneg = 84%)和COPD(kappa = 0.48) ,ppos = 53%,pneg = 95%)。当结缔组织疾病问题被修改时,该项目的一致性得到改善(kappa = 0.47,ppos = 50%)。结论:PRO-CCI可作为HNC患者预后和结果研究的简便有效工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号